Bently Doonan, MD, examines emerging therapies for metastatic melanoma. He identifies LAG3 inhibition and its role in melanoma. He helps to familiarize physicians with TIL therapy and he discusses outpatient systemic cytokine therapy for relapsed metastatic melanoma